November 24, 2016 - By Nellie Frank
Isaac Ciechanover, the Chief Executive Officer of Atara Biotherapeutics Inc, unloaded 12,000 shares of the company, worth approximately $220,106 USD, based on $18.3 for each share. It seems he is very active lately as in the last month, he silently sold additional 4,800 shares of the company, worth $66,264 USD. Isaac Ciechanover currently holds 1.12 million shares or 3.65% of Atara Biotherapeutics Inc’s market cap. The insider shares were unloaded on November 23, 2016 and the Form 4 that contains the original information, filed with the D.C. based-SEC can be accessed here.
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. $80 is the highest target while $8 is the lowest. The $36.50 average target is 87.66% above today’s ($19.45) stock price. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) earned “Buy” rating by Canaccord Genuity on Wednesday, September 9. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Sell” rating given on Tuesday, December 15 by Citigroup. The firm has “Sell” rating by Goldman Sachs given on Thursday, September 15. As per Tuesday, December 15, the company rating was maintained by JMP Securities. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) earned “Mkt Perform” rating by JMP Securities on Friday, September 25. The firm has “Outperform” rating by William Blair given on Friday, October 9. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, November 18. The firm earned “Sell” rating on Friday, August 19 by Citigroup. The firm earned “Buy” rating on Monday, October 24 by Jefferies.
Insitutional Activity: The institutional sentiment decreased to 1.48 in 2016 Q2. Its down 1.88, from 3.36 in 2016Q1. The ratio worsened, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Moreover, Fmr Ltd Liability Com has 0.01% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 3.13M shares. Rtw accumulated 465,874 shares or 3.58% of the stock. The Illinois-based Northern Trust has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Invesco Limited holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 110,197 shares. Eagle Asset Mngmt Incorporated holds 972,592 shares or 0.15% of its portfolio. Morgan Stanley has 3,781 shares for 0% of their US portfolio. The Washington-based Parametric Portfolio Associate Limited Liability has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Blackrock Advsrs Ltd Llc owns 10,186 shares or 0% of their US portfolio. Neuberger Berman Gp Limited Co last reported 629,120 shares in the company. Jpmorgan Chase Comm last reported 0% of its portfolio in the stock. Tiaa Cref Investment Mgmt Ltd Liability Corp, a New York-based fund reported 71,630 shares. Moreover, Bancshares Of New York Mellon has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 99,629 shares. State Street, a Massachusetts-based fund reported 355,001 shares. Brown Brothers Harriman & Communications last reported 0% of its portfolio in the stock. Blackrock Fund accumulated 0% or 913,922 shares.
Insider Transactions: Since May 25, 2016, the stock had 0 buys, and 18 selling transactions for $2.36 million net activity. Ciechanover Isaac E. sold $212,208 worth of stock. 7,068 shares with value of $126,164 were sold by Haqq Christopher on Monday, November 21. 16,718 shares were sold by Soffer Gad, worth $334,421. Gallagher Carol Giltner also sold $22,910 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares. On Thursday, November 10 the insider MCGRATH JOHN sold $99,175. Shares for $58,492 were sold by Clark Mitchall G.
The stock increased 6.28% or $1.15 on November 23, hitting $19.45. About 196,158 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 6.80% since April 22, 2016 and is downtrending. It has underperformed by 12.21% the S&P500.
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $552.29 million. The Company’s segment is the business of developing and commercializing therapeutics. It currently has negative earnings. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Analysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings on March, 2. They expect $-0.94 EPS, down 25.33% or $0.19 from last year’s $-0.75 per share. After $-0.88 actual EPS reported by Atara Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 6.82% negative EPS growth.
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Fool.com which released: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Also Marketwatch.com published the news titled: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank